Publications by authors named "Duerr U"
Article Synopsis
- Clinical trials have shown that SGLT2 inhibitors like dapagliflozin benefit adults with diabetic and chronic kidney diseases, but their effects on younger patients, especially those with Alport syndrome, remain unclear.
- The DOUBLE PRO-TECT Alport trial will involve participants aged 10 to 39 with a confirmed diagnosis of Alport syndrome and elevated albumin levels, testing the drug's safety and efficacy over 48 weeks compared to a placebo.
- The study aims to measure changes in urinary albumin-to-creatinine ratio (UACR) and kidney function to determine if these inhibitors can help protect against kidney failure in young patients.
Background: Clinical trials require great effort, time, expertise, and money. For clinicians at university hospitals with their full work load of teaching and medical care, the planning of an investigator-initiated clinical trial seems almost unthinkable. Despite their expertise in distinct diseases, university clinicians lack the time necessary to organize the funding and to initiate and conduct Phase III clinical trials in adults or in children.
View Article and Find Full Text PDF